We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

66 hedge funds and large institutions have $208M invested in Protagonist Therapeutics in 2019 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 16 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 16

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

10% more capital invested

Capital invested by funds: $189M → $208M (+$19.2M)

9.09% more ownership

Funds ownership: 64.51% → 73.6% (+9.1%)

3% more funds holding

Funds holding: 64 → 66 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
66
Holders Change
+2
Holders Change %
+3.13%
% of All Funds
1.43%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
30
Reduced
16
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$8.22M
2
BBA
Baker Bros. Advisors
New York
+$6.54M
3
ACP
Acuta Capital Partners
California
+$3.69M
4
JP Morgan Chase
JP Morgan Chase
New York
+$3.07M
5
VMI
VHCP Management III
New York
+$2.91M

Top Sellers

Rank Fund Capital Flow
1
GTC
Ghost Tree Capital
New York
-$5.53M
2
FCM
Farallon Capital Management
California
-$3.21M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$3.05M
4
WCM
Wedge Capital Management
North Carolina
-$1.7M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$42.5M -$1.08M -97,845 -3%
FCM
2
Farallon Capital Management
California
$18.2M -$3.21M -290,000 -16%
VMI
3
VHCP Management III
New York
$13M +$2.91M +263,025 +32%
BI
4
BVF Inc
California
$12.9M -$657K -59,453 -5%
BlackRock
5
BlackRock
New York
$12.3M +$8.22M +743,632 +272%
BBA
6
Baker Bros. Advisors
New York
$12.1M +$6.54M +591,189 +146%
Millennium Management
7
Millennium Management
New York
$9.82M -$908K -82,089 -9%
Vanguard Group
8
Vanguard Group
Pennsylvania
$9.69M +$1.12M +100,960 +14%
Dimensional Fund Advisors
9
Dimensional Fund Advisors
Texas
$9.01M +$888K +80,281 +12%
ACP
10
Acuta Capital Partners
California
$8.13M +$3.69M +334,000 +99%
JP Morgan Chase
11
JP Morgan Chase
New York
$6.69M +$3.07M +278,066 +99%
Renaissance Technologies
12
Renaissance Technologies
New York
$6.2M +$1.19M +107,300 +26%
VMI
13
VHCP Management II
New York
$5.17M +$1.72M +155,404 +57%
Citadel Advisors
14
Citadel Advisors
Florida
$4.96M +$510K +46,120 +13%
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$4.81M +$1.54M +139,550 +54%
State Street
16
State Street
Massachusetts
$3.18M +$2.75M +248,658 +1,770%
OAM
17
Oxford Asset Management
United Kingdom
$2.61M +$816K +73,811 +52%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$2.47M +$787K +71,207 +54%
GTC
19
Ghost Tree Capital
New York
$2.42M -$5.53M -500,000 -71%
Two Sigma Advisers
20
Two Sigma Advisers
New York
$1.51M +$345K +31,200 +33%
Allianz Asset Management
21
Allianz Asset Management
Germany
$1.5M +$522K +47,175 +61%
Two Sigma Investments
22
Two Sigma Investments
New York
$1.48M +$843K +76,247 +166%
TCM
23
Tekla Capital Management
Massachusetts
$1.47M -$620K -56,084 -32%
BFM
24
Boothbay Fund Management
New York
$1.28M +$1.17M +105,965 New
UBS Group
25
UBS Group
Switzerland
$1.26M +$1.13M +102,556 +6,234%
1
2 3 4

PTGX Hedge Fund Activity: Q2 2019 in Review

66 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2019, worth a combined $208M — up 10% from $189M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new PTGX positions and 13 closed out — a net gain of 2 holders — while 30 added to existing stakes and 16 trimmed.

The largest buyer was BlackRock, adding an estimated $8.22M. The largest seller was Ghost Tree Capital, cutting an estimated $5.53M.

  • 66 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2019, up from 64 in Q1 2019.
  • Funds reported $208M of Protagonist Therapeutics stock for Q2 2019, up 10% quarter-over-quarter.
  • 15 funds opened new Protagonist Therapeutics positions in Q2 2019 and 13 closed out, a net change of +2 holders.
  • The largest Protagonist Therapeutics buyer in Q2 2019 was BlackRock, an estimated $8.22M added.
  • The largest Protagonist Therapeutics seller in Q2 2019 was Ghost Tree Capital, an estimated $5.53M sold.

Based on aggregated 13F filings for Q2 2019.